STORY FROM: Drugs & Medical Devices

FDA Adds Boxed Warning to Singulair Regarding Behavior, Mood-Related Changes

WASHINGTON, D.C. — The Food and Drug Administration says it is adding a boxed warning to Merck's asthma and allergy drug Singulair (montelukast) and generic equivalents regarding serious behavior and mood-related changes.

In a March 4 MedWatch Safety Alert, the agency explained that it decided “a stronger warning is needed after conducting an extensive review of available information and convening a panel of outside experts.”

“We are taking this action after a review of available information led us to reevaluate the benefits and risks of montelukast use,” the alert says. “Montelukast prescribing information already includes warnings about mental health side ...

Registered User Login